Your browser doesn't support javascript.
loading
Investigating topical delivery of erythromycin laden into lipid nanocarrier for enhancing the anti-bacterial activity.
Elsewedy, Heba S; Alshehri, Sultan; Alsammak, Naheda S; Abou Chahin, Nada F; Alotaibi, Manal S; Alshammari, Rehab A; Shehata, Tamer M; Aldhubiab, Bandar; Soliman, Wafaa E.
Afiliação
  • Elsewedy HS; Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh 13713, Saudi Arabia.
  • Alshehri S; Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
  • Alsammak NS; Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh 13713, Saudi Arabia.
  • Abou Chahin NF; Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh 13713, Saudi Arabia.
  • Alotaibi MS; Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh 13713, Saudi Arabia.
  • Alshammari RA; Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh 13713, Saudi Arabia.
  • Shehata TM; Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Saudi Arabia.
  • Aldhubiab B; Department of Pharmaceutics, College of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
  • Soliman WE; Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Saudi Arabia.
Saudi Pharm J ; 32(9): 102152, 2024 Sep.
Article em En | MEDLINE | ID: mdl-39165579
ABSTRACT
Skin infections considered as one of the predominant disorders that could greatly influence humans. Topical drug delivery is believed to be an effective substitute to systemically delivered medication for skin disorders management. Erythromycin has been proven to retain anti-bacterial activity. Based on that, the aim of existent study is to develop a proper nanocarrier, namely; nanoemulsion using tea tree oil including Erythromycin. Applying quality by design approach, the optimized nanoemulsion was selected based on number of independent variables namely; particle size and in vitro release study. Yet, in order to get appropriate topical application, the optimized nanoemulsion was combined with previously prepared hydrogel base to provide Erythromycin based nanoemulgel. The developed nanoemulgel was assessed for its organoleptic and physical characters to ensure its suitability for topical application. Stability study was implemented over three months after being kept in two distinct environments. Eventually, the antibacterial behavior of the preparation was investigated on MRSA to verify the expected antibacterial improvement and validate the effectiveness of the developed nanocarrier. The formulation showed consistent appearance, with pH (6.11 ± 0.19), viscosity (10400 ± 1275 cP), spreadability (54.03 ± 2.3 mm), extrudability (80.36 ± 3.15 g/cm2) and drug content (99.3 ± 0.46 %) that seemed to be satisfied for topical application. It could provide 48.1 ± 4.2 % releases over 6 h in addition to be stable at room temperature and at refrigerator. Ultimately, the formula showed a significant antibacterial activity against MRSA proving the combination and the nanocarrier effectiveness.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article